COVID-19 treatment

URSAPHARM Arzneimittel y CEBINA anuncian una colaboración para readaptar el antihistamínico azelastine para combatir la COVID-19

(PRESS RELEASE) SAARBRÜCKEN / VIENA, 17-Feb-2021 — /EuropaWire/ — En la lucha contra el virus SARS-CoV-2, una gran cantidad de…

3 years ago

URSAPHARM Arzneimittel and CEBINA announce partnership to repurpose the antihistamine azelastine to combat COVID-19

(PRESS RELEASE) SAARBRÜCKEN / VIENNA, 17-Feb-2021 — /EuropaWire/ — In the fight against the SARS-CoV-2 virus, a large number of…

3 years ago

EIB signs €15.0 million financing deal with AB Science to support the development of masitinib as a treatment for COVID-19

Financing deal worth €15.0 million signed to support clinical development programme for masitinib Masitinib developed as a credible candidate for treating…

3 years ago